Dragonfly Research is the research arm of The Elliot Lewis Center. Dragonfly Research is currently conducting many clinical trials for relapsing and progressive forms of MS. Ongoing research includes phase II and phase III clinical trials, as well as phase IV observational trials, investigating the efficacy of new and existing MS drugs.
The Elliot Lewis Center is actively participating in approximately 20 multiple sclerosis clinical trials. Recent trials have included recently approved Ocrevus. Our center also participates in clinical trials with treatments under study and not yet available for relapsing and progressive forms of MS.
Enrolling studies at Dragonfly Research change regularly, and enrollment is limited so we encourage you to contact us as soon as possible and check this page frequently. Our Clinical Research Coordinators, can be reached at 781-591-8313.
The Elliot Lewis Center and Dragonfly Research also conduct independent research projects to address important clinical issues.
Clinical Trial Opportunity for Patients with Primary Progressive & Secondary Progressive MS:
The Elliot Lewis Center is currently participating in a clinical trial for patients with Primary and Secondary Progressive MS aged 18-65. Patients will receive Ocrevus for 4 years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan.
In addition to collecting safety data, the study is investigating the use of smartphones to track patient symptoms. 75% of patients who enter the trial will receive a smartphone with daily and weekly tasks, tracking day-to-day symptoms.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Clinical Trial Opportunity for Patients with Relapsing MS:
Patients with Relapsing MS currently receiving treatment with Tysabri may be eligible for a trial investigating 6-week Tysabri dosing. Patients will receive Tysabri for 2 years through the study and will be randomized to either a 4-week or 6-week dosing schedule.
The study is collecting safety and efficacy data on both Tysabri dosing schedules. To be eligible, patients must be aged 18-60, have received at least one year of Tysabri treatment, and be able to walk without assistance. Patients must not have received Ocrevus, Lemtrada, Rituxan, or Zinbryta in the past two years.
The study requires MRIs every 6 months. The Tysabri, MRIs, assessments, and physician appointments are all covered by the study.
Clinical Trial Opportunity for Newly Diagnosed Patients with Relapsing MS:
We are currently enrolling newly diagnosed, treatment naïve patients into a 4-year Ocrevus study. Patients aged 18-55 with MS symptoms that began within the past 3 years may be eligible.
This study is investigating infusing Ocrevus at a faster rate. Beginning at their 6 month dose, patients will be randomized to receive Ocrevus at either the standard rate over 3.5 hours or at an increased rate over 2 hours.
Patients may not have been treated with ANY previous MS therapy. The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Clinical Trial Opportunity for Patients with Relapsing & Secondary Progressive MS:
Patients aged 18-65 with Relapsing or Secondary Progressive MS may be eligible for treatment with Siponimod, an investigational MS therapy.
This study is tracking the tolerability of Siponimod and any potential immune effects. Siponimod is a once-daily pill and patients will receive 6 months of treatment through the study. After completing the study, patients will have the option to receive Siponimod through a managed access program until it becomes commercially available.
Patients must currently be treated with any oral or injectable MS therapy. Certain previous MS therapies may be exclusionary. The study requires 4 visits over the course of 6 months and does not require any MRIs. The medication, assessments, and physician appointments are covered by the study.
Contact the research coordinators at The Elliot Lewis Center for more information.